Philogen SpA (DE:78Q) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Philogen S.p.A. is conducting a Phase 2 clinical study titled ‘A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.’ The study aims to evaluate the activity, safety, and efficacy of intratumoral L19IL2/L19TNF in patients with locally advanced basal cell carcinoma who have not responded to or cannot tolerate systemic treatments.
The intervention being tested is the drug L19IL2/L19TNF, which is administered intratumorally. This treatment is designed to target injectable cutaneous and subcutaneous lesions, providing a localized approach to managing basal cell carcinoma.
This open-label, single-arm, multicenter study involves a single group of patients receiving weekly intratumoral injections of L19IL2/L19TNF for up to four weeks. The primary purpose is treatment, with no masking involved, allowing for direct observation of the drug’s effects.
The study is set to begin recruiting on November 7, 2025, with the latest update submitted on December 10, 2025. These dates are crucial as they mark the initiation of patient involvement and the most recent developments in the study’s progress.
The update on this study could influence Philogen’s stock performance positively, as successful outcomes may enhance investor confidence and market position. The study’s progress is particularly relevant in the competitive landscape of cancer treatment innovations.
The study is ongoing, with further details available on the ClinicalTrials portal.
To learn more about DE:78Q’s potential, visit the Philogen SpA drug pipeline page.